CVR 24053415Public limited company (A/S)Fremstilling af medicinske og dentale instrumenter samt udstyr hertil (325000)Secondary industries: Fremstilling af andre færdige metalprodukter i.a.n. (259900)StruerFounded 20 Dec 1930
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Phillips-Medisize A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
233
CVR, Aug 2026
-9 (-3.7%) over 12 months
Revenue
425.8M
DKK, group, annual report 2025
+0.1% on 2024
Result
+35.4M
DKK, group, annual report 2025
Equity
148.9M
DKK, group, annual report 2025
Phillips-Medisize Holdings A/SCVR 37705497, 100% of capital and votes
Operating company
Dandex estimate: 233 employees registered in 2026Cecilie Rørbyesince 5 Nov 2024
Owners of 5% or more. CVR registers shares in bands, not exact figures.
CVR 37705497100% of capital and votessince 31 May 2016
CVR 4125791133.3% to under 50% of capital and votes5 Feb 2013 to 12 Apr 2015
5% to under 10% of capital and votesnotified 11 Jun 20155 Feb 2013 to 30 May 2016
CVR 2897166466.7% to under 90% of capital and votesnotified 11 Jun 20155 Feb 2013 to 30 May 2016
CVR 369051905% to under 10% of capital and votes11 Jun 2015 to 30 May 2016
Ultimate controller
Molex International Holdings S.à r.l.
Holding in Phillips-Medisize Holdings A/S, since 18 Dec 2025
Holding company
Phillips-Medisize Holdings A/S
CVR 37705497Public limited company (A/S)
Holding in Phillips-Medisize A/S, since 31 May 2016
This company
Phillips-Medisize A/S
CVR 24053415
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Showing 25 of 43. The list above has every one.
Aug 2026, monthly: 233 employees, 217 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | Q1 2010 | Q2 2010 | Q3 2010 | Q4 2010 | 2011 | 2012 | 2013 | 2014 | Jan 2015 | Feb 2015 | Mar 2015 | Apr 2015 | May 2015 | Jun 2015 | Jul 2015 | Aug 2015 | Sep 2015 | Oct 2015 | Nov 2015 | Dec 2015 | Jan 2016 | Feb 2016 | Mar 2016 | Apr 2016 | May 2016 | Jun 2016 | Jul 2016 | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Sep 2017 | Oct 2017 | Nov 2017 | Dec 2017 | Jan 2018 | Feb 2018 | Mar 2018 | Apr 2018 | May 2018 | Jun 2018 | Jul 2018 | Aug 2018 | Sep 2018 | Oct 2018 | Nov 2018 | Dec 2018 | Jan 2019 | Feb 2019 | Mar 2019 | Apr 2019 | May 2019 | Jun 2019 | Jul 2019 | Aug 2019 | Sep 2019 | Oct 2019 | Nov 2019 | Dec 2019 | Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 | Jan 2022 | Feb 2022 | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 176 | 203 | 217 | 210 | 304 | 241 | 149 | 143 | 154 | 102 | 93 | 83 | 90 | No count | No count | No count | No count | 51 | 56 | 75 | 87 | 86 | 87 | 91 | 81 | 82 | 84 | 85 | 82 | 83 | 84 | 87 | 88 | 88 | 90 | 91 | 91 | 94 | 93 | 90 | 91 | 90 | 88 | 88 | 89 | 89 | 91 | 91 | 97 | 90 | 93 | 90 | 93 | 96 | 93 | 92 | 93 | 93 | 93 | 96 | 100 | 96 | 98 | 99 | 102 | 100 | 104 | 105 | 104 | 105 | 106 | 111 | 124 | 117 | 116 | 119 | 125 | 135 | 143 | 148 | 145 | 146 | 146 | 148 | 154 | 154 | 157 | 160 | 165 | 163 | 163 | 161 | 165 | 169 | 169 | 174 | 174 | 178 | 181 | 179 | 189 | 190 | 191 | 198 | 196 | 197 | 202 | 200 | 211 | 215 | 230 | 226 | 229 | 235 | 235 | 233 | 232 | 233 | 233 | 231 | 230 | 232 | 228 | 225 | 229 | 225 | 234 | 231 | 231 | 232 | 230 | 232 | 234 | 239 | 234 | 233 | 233 | 233 | 235 | 239 | 239 | 241 | 239 | 243 | 242 | 244 | 244 | 243 | 242 | 241 | 238 | 239 | 238 | 239 | 234 | 233 | 234 | 233 | 234 | 228 | 233 |
| FTE | 145 | 188 | 211 | 215 | 258 | 272 | 170 | 119 | 136 | 109 | 75 | 81 | 80 | 71 | 64 | 56 | 56 | 54 | 51 | 63 | 78 | 82 | 82 | 84 | 79 | 80 | 83 | 80 | 76 | 80 | 81 | 82 | 81 | 85 | 85 | 86 | 90 | 90 | 88 | 87 | 82 | 86 | 85 | 85 | 84 | 87 | 87 | 87 | 92 | 87 | 89 | 88 | 90 | 91 | 89 | 90 | 91 | 92 | 91 | 94 | 98 | 94 | 96 | 97 | 100 | 98 | 101 | 102 | 102 | 102 | 104 | 107 | 118 | 113 | 113 | 116 | 118 | 132 | 130 | 145 | 142 | 141 | 141 | 140 | 150 | 152 | 153 | 150 | 136 | 159 | 157 | 157 | 161 | 163 | 165 | 164 | 167 | 168 | 171 | 169 | 176 | 183 | 185 | 190 | 189 | 189 | 195 | 194 | 206 | 210 | 227 | 219 | 217 | 228 | 230 | 227 | 226 | 225 | 228 | 220 | 224 | 224 | 223 | 219 | 220 | 222 | 226 | 226 | 227 | 223 | 225 | 227 | 228 | 228 | 229 | 225 | 220 | 224 | 225 | 229 | 236 | 229 | 228 | 232 | 237 | 232 | 232 | 228 | 225 | 228 | 225 | 229 | 226 | 222 | 222 | 219 | 225 | 224 | 224 | 218 | 217 |
| Series | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Quarterly | Quarterly | Quarterly | Quarterly | Annual | Annual | Annual | Annual | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group. CVR changed its monthly method in Oct 2019: a step there need not be real.
Source: CVR, latest Aug 2026, published 21 Oct 2026.
Group figures (koncern) for 2021 and 2023 to 2025, the company's own for 2022, in DKK, from the annual reports filed in XBRL.
2025, DKK: Revenue 425.8M, Gross profit 100.4M, Operating profit 49.5M, Result for the year 35.4M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 198.5M, Equity 148.9M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2021group | 2022 | 2023group | 2024group | 2025group |
|---|---|---|---|---|---|
| Revenue | 360,602 | 378,000 | 481,932 | 425,551 | 425,791 |
| Gross profit | 80,834 | 91,841 | 171,043 | 72,758 | 100,350 |
| Operating profit | +50,244 | +64,000 | +113,464 | +18,103 | +49,533 |
| Result for the year | +36,944 | +49,000 | +83,423 | +12,144 | +35,364 |
| Equity | 108,791 | 158,000 | 241,391 | 113,536 | 148,900 |
| Total assets | 244,609 | 320,921 | 385,425 | 242,310 | 198,472 |
| Employees (average) | Not reported | 217 | Not reported | Not reported | Not reported |
| Credit metrics (Dandex calculations) | |||||
| Revenue growth (omsætningsvækst) | 31.3% | 4.7% | 27.5% | -11.7% | 0.1% |
| EBIT margin (overskudsgrad) | 13.9% | 16.9% | 23.5% | 4.3% | 11.6% |
| EBITDA | Not reportednote 1 | 69,790 | Not reportednote 1 | Not reportednote 1 | 53,936 |
| EBITDA margin (EBITDA-margin) | Not reportednote 1 | 18.5% | Not reportednote 1 | Not reportednote 1 | 12.7% |
| Employee growth (vækst i antal ansatte) | Not reportednote 2 | 20.6% | Not reportednote 2 | Not reportednote 2 | Not reportednote 2 |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | 3,887 | 9,315 | 5,732 | 6,790 | 563 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions.
Large listed filers report IFRS figures in an ESEF report, for the group where there is one.
How each credit metric is calculated:
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for Phillips-Medisize A/S:
Have Pro? Sign in.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move. Implied value is the whole capital after the step at its cash price, not a valuation.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCash, debt conversionPaid in 5,199,693, cash price 1.07, implied value 17,924,003 | 1.07 | 5,199,693 | 17,924,003 | 16,778,061 | |
| IncreaseDebt conversionPaid in 2,548,918 | None | 2,548,918 | None | 11,920,918 | |
| IncreaseCashPaid in 9,999,685, cash price 7.29, implied value 68,306,885 | 7.29 | 9,999,685 | 68,306,885 | 9,372,000 | |
| IncreaseDemergerPaid in 34,644,000 | None | 34,644,000 | None | 8,000,000 | |
| FoundingNot read from the announcement | None | None | None | 2,000,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Demerger (spaltning), as the receiving company (modtagende selskab)
Source: CVR, read 18 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 18 Nov 2026.
The newest 50 of 63 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Bestyrelse:
Fratrådte:
Katherine Mary Dornan, den 08.11.2024.
Tiltrådte:
Sean David Rice, den 08.11.2024.
Direktion:
Fratrådte:
Brett Alan Landrum, (adm. dir), den 05.11.2024.
Tiltrådte:
Cecilie Rørbye, (adm. dir), den 05.11.2024.
Direktion:
Fratrådte:
Katrine Eggert Hammer, (adm. dir), den 31.03.2024.
Tiltrådte:
Brett Alan Landrum, (adm. dir), den 31.03.2024.
Vedtægter ændret: 27.11.2023
Direktion:
Fratrådte:
Søren Vestergård Jacobsen, (adm. dir), den 01.11.2021.
Tiltrådte:
Katrine Eggert Hammer, (adm. dir), den 01.11.2021.
Bestyrelse:
Fratrådte:
William Patrick Welch, den 12.10.2021.
Tiltrådte:
Brett Alan Landrum, den 12.10.2021.
Bestyrelse:
Fratrådte:
Matthew Jon Jennings, (formand), den 01.12.2019, Norman Charles Roegner III, den 01.12.2019.
Tiltrådte:
David William Cole, (formand), den 01.12.2019, Katherine Mary Dornan, den 01.12.2019.
Revision:
Fratrådte:
ERNST & YOUNG Godkendt Revisionspartnerselskab, den 01.12.2019.
Tiltrådte:
CVR-NR. 34209936 GRANT THORNTON,STATSAUTORISERET REVISIONSPARTNERSELSKAB, Stockholmsgade 45, 2100 København Ø, den 01.12.2019.
Revision:
Fratrådte:
PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 04.12.2018.
Tiltrådte:
CVR-NR. 30700228 ERNST & YOUNG Godkendt Revisionspartnerselskab, Vestre Havnepromenade 1A, 9000 Aalborg, den 04.12.2018.
Vedtægter ændret: 17.10.2018
Nyt binavn: Medicom Innovation Partner a/s
Slettet binavn: Medicom Innovation Partner A/S
Direktion:
Fratrådte:
Morten Nielsen (adm. dir), den 31.07.2018.
Tiltrådte:
Søren Vestergård Jacobsen (adm. dir), den 01.08.2018.
Vedtægter ændret: 18.09.2018
Nyt navn: Phillips-Medisize A/S
Nyt binavn: Medicom Innovation Partner A/S
Slettede binavne: MEDICOM NORDIC A/S, Bang & Olufsen Medicom a/s
Bestyrelse:
Fratrådte:
John Charles Sills, den 23.02.2018.
Tiltrådte:
Norman Charles Roegner III, den 23.02.2018.
Vedtægter ændret: 08.08.2016
Selskabet tegnes af den samlede bestyrelse, af bestyrelsesformanden i forening med en direktør eller af to medlemmer af bestyrelsen i forening med en direktør..
Bestyrelse:
Fratrådte:
Mads Peter Hytteballe Andersen (formand), den 31.05.2016, Alejandra Maria Cristina Bonifacini Mørk, den 31.05.2016, Peer Nørkjær (næstformand), den 31.05.2016, Nicholas Hughes, den 31.05.2016.
Tiltrådte:
John Charles Sills, den 31.05.2016, Matthew Jon Jennings (formand), den 31.05.2016, William Patrick Welch, den 31.05.2016.
Vedtægter ændret: 31.05.2016
CVR-nummer:
24053415.
NAVN:
BANG & OLUFSEN MEDICOM A/S.
Adresse: Gimsinglundvej 20, 7600 Struer.
Kommune: Struer.
Vedtægter ændret: 31.08.2015
Nyt navn: Medicom Innovation Partner a/s
Nyt binavn: Bang & Olufsen Medicom a/s
CVR-nummer
24053415.
NAVN:
BANG & OLUFSEN MEDICOM A/S.
Adresse: Gimsinglundvej 20, 7600 Struer.
Kommune: Struer.
Vedtægter ændret: 01.04.2015
CVR-nummer
24053415.
NAVN:
BANG & OLUFSEN MEDICOM A/S.
Adresse: Gimsinglundvej 20, 7600 Struer.
Kommune: Struer.
Bestyrelse:
Udtrådt af bestyrelsen:
Kim Hyldahl Hansen, den 28.05.2014.
Indtrådt i bestyrelsen:
Mogens Elbrønd Pedersen, den 28.05.2014.
Bestyrelse:
Udtrådt af bestyrelsen:
Erik Trock-Jansen, den 10.08.2012.
Indtrådt i bestyrelsen:
Mads Peter Hytteballe Andersen (formand), den 10.08.2012.
Vedtægter ændret:
30.12.2011.
Kapitalforhøjelse kr. 3.157.143,00: kr. 270.612,00 indbetalt ved konvertering af gæld, kurs 110,85. kr. 2.886.531,00 indbetalt kontant, kurs 110,85.
Kapitalen udgør herefter kr. 16.778.061,00.
Vedtægter ændret:
30.12.2011.
Kapitalforhøjelse:
kr. 1.700.000,00 indbetalt kontant, kurs 100,00.
Kapitalen udgør herefter kr. 13.620.918,00.
Revision:
Udtrådt af revisionen:
PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSAKTIESELSKAB, den 01.07.2011.
Indtrådt i revisionen:
PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, Jens Chr.Skous Vej 1, 8000 Aarhus C, den 01.07.2011.
Bestyrelse:
Fratrådt som formand tiltrådt som næstformand: Peer Nørkjær, den 12.04.2011.
Indtrådt i bestyrelsen:
Erik Trock-Jansen (formand), den 12.04.2011.
Direktion:
Udtrådt af direktionen:
Erik Trock-Jansen, den 12.04.2011.
Indtrådt i direktionen:
Morten Nielsen (adm. dir), den 12.04.2011.
Vedtægter ændret:
30.12.2010.
Kapitalforhøjelse:
kr. 2.548.918,00 indbetalt ved konvertering af gæld, kurs 100,00.
Kapitalen udgør herefter kr. 11.920.918,00.
Direktion:
Udtrådt af direktionen:
Henrik Kagenow, den 01.06.2010.
Indtrådt i direktionen:
Adm. direktør Erik Trock-Jansen (adm. dir), den 01.06.2010.
Vedtægter ændret:
22.12.2008.
Kapitalforhøjelse:
kr. 1.372.000,00 indbetalt kontant, kurs 728,84.
Kapitalen udgør herefter kr. 9.372.000,00.
Bestyrelse:
Udtrådt af bestyrelsen:
Peter Thostrup, den 01.10.2008.
Indtrådt i bestyrelsen:
Kim Bo Hansen, den 01.10.2008.
Vedtægter ændret:
21.12.2007.
Vedtægter ændret:
15.10.2007.
Nyt binavn: MEDICOM NORDIC A/S (BANG & OLUFSEN MEDICOM A/S).
Selskabet tegnes af den samlede bestyrelse, af bestyrelsesformanden i forening med en direktør eller af bestyrelsesformanden og næstformanden i forening eller af 2 medlemmer af bestyrelsen i forening med en direktør.
Revision:
Udtrådt af revisionen:
CVR-NR. 24213714 DELOITTE STATSAUTORISERET REVISIONSAKTIESELSKAB, den 15.10.2007.
Indtrådt i revisionen:
PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSAKTIESELSKAB, Jens Chr. Skous Vej 1, 8000 Århus C, den 15.10.2007.
Vedtægter ændret:
10.08.2007.
Regnskabsår ændret til:
01.01 - 31.12.
Omlægningsperiode:
01.06.2007 - 31.12.2007.
Vedtægter ændret:
01.03.2007.
Vedtægter ændret:
01.03.2007.
Bestyrelse:
Fratrådt som formand, men forbliver i bestyrelsen: Peter Thostrup, den 01.03.2007.
Udtrådt af bestyrelsen:
Henrik Kagenow, den 01.03.2007, Torben Ballegaard Sørensen, den 01.03.2007.
Indtrådt i bestyrelsen:
Cand. Pharm., HD(A) Peer Nørkjær (formand), den 01.03.2007, Alejandra Maria Cristina Bonifacini Mørk, den 01.03.2007.
Aktiver og gæld er overdraget til CVR-NR. 29806357 BANG & OLUFSEN EJENDOMME A/S.
Erhvervs- og Selskabsstyrelsen har modtaget
spaltningsplan i henhold til aktieselskabslovens § 136 a
angående den påtænkte spaltning af
CVR-NR. 24053415 BANG & OLUFSEN MEDICOM A/S.
De øvrige deltagende selskaber er et/flere
nye selskaber.
Endvidere er modtaget erklæring fra
vurderingsmændene i henhold til aktieselskabslovens §
136 c, stk. 4.
Ny adresse:
Gimsinglundvej 20, 7600 Struer.
Direktion:
Udtrådt af direktionen:
Jens Peter Zinck, den 31.05.2006.
Revision:
Udtrådt af revisionen:
PricewaterhouseCoopers Nobelparken, den 28.09.2005.
Direktion:
Fratrådt som adm. direktør tiltrådt som adm.dir.: Henrik Kagenow, den 20.10.2003.
Indtrådt i direktionen:
Jens Peter Zinck, den 20.10.2003.
Bestyrelse:
Udtrådt af bestyrelsen:
Carl Henrik Jeppesen , Thomas Kristensen.
Indtrådt i bestyrelsen:
Direktør Torben Ballegaard Sørensen, Adm. direktør Henrik Kagenow.
Bestyrelse:
Tiltrådt som formand:
Peter Thostrup, den 22.09.2000.
Udtrådt af bestyrelsen:
Anders Jørn Knutsen, den 22.09.2000.
Indtrådt i bestyrelsen:
Direktør Thomas Kristensen, den 22.09.2000.
Vedtægter ændret:
19.05.1999.
Nyt navn:
BANG & OLUFSEN MEDICOM A/S.
Ny adresse:
c/o BANG & OLUFSEN HOLDING A/S, Peter Bangs Vej 15, 7600 Struer.
Slettet binavn: BANG & OLUFSEN EXPORT A/S (BANG & OLUFSEN TECHNOLOGY A/S).
Revision:
Udtrådt af revisionen:
PricewaterhouseCoopers.
Indtrådt i revisionen:
PricewaterhouseCoopers, 8000 Århus C.
Bestyrelse:
Udtrådt af bestyrelsen:
Henning Vestergaard, den 01.03.1999.
Indtrådt i bestyrelsen:
Jørgen Purup, den 01.03.1999.
Revision:
Udtrådt af revisionen:
PRICE WATERHOUSE/SEIER-PETERSEN STATSAUTORISERET REVISIONSAKTIESELSKAB.
Indtrådt i revisionen:
DELOITTE & TOUCHE STATSAUTORISERET REVISIONSAKTIESELSKAB, H.C. Andersens Boulevard 2, 1780 København V.
Bestyrelse:
Udtrådt af bestyrelsen:
Indtrådt i bestyrelsen:
Direktør Henning Vestergaard, Direktør Carl Henrik Jeppesen.
Direktion:
Udtrådt af direktionen:
Indtrådt i direktionen:
Adm. direktør Henrik Kagenow (adm. direktør).
P-number 100639097115, 9999 Ukendt
P-number 1010699211Gimsinglundvej 20, 7600 Struer
P-number 1008700016Arne Jacobsens Allé 7, 2300 København S
P-number 1025308391Teknikerbyen 5, 2830 Virum
P-number 1002916650Gimsinglundvej 20, 7600 Struer